Search Mark
Home / Industry Dynamics

Pfizer and AstraZeneca Pour Nearly USD1Billion in French Research


Today’s News 

Pfizer and AstraZeneca are making a significant mark in France’s research landscape with a nearly USD 1 billion investment, showcasing their confidence in the country’s potential for healthcare innovation at the ‘Choose France’ business summit. 

Leading healthcare giants Pfizer and AstraZeneca announced new combined investments of nearly USD 1 billion in France. 

Image Source: The Royal Australian College of General Practitioners (RACGP)
Leading healthcare giants Pfizer and AstraZeneca announced new combined investments of nearly USD 1 billion in France. 
Image Source: The Royal Australian College of General Practitioners (RACGP) 

Leading pharmaceutical companies Pfizer and AstraZeneca have unveiled ambitious investment plans for France, collectively amounting to nearly USD 1 billion. Pfizer, with a commitment of 500 million euros (USD 538.5 million), aims to bolster its research and development initiatives within the country. Meanwhile, AstraZeneca has announced a substantial investment of USD 388 million in its Dunkirk site. 

Pfizer and AstraZeneca are two pharmaceutical giants in the industry. 
Image Source: Financial Times 
The coronavirus Covid-19 vaccines of Pfizer and AstraZeneca side-by-side. 
Image Source: Reuters 

These significant pledges come on the eve of the annual ‘Choose France’ business summit, signaling a vote of confidence in the French economy. President Emmanuel Macron, poised to inaugurate the event, views it as a strategic platform to attract prominent international businesses and investors. 

In tandem with these pharmaceutical investments, France has also witnessed other notable developments, including the creation of 100 new jobs in Paris by Wall Street giant Morgan Stanley and commitments from firms such as German aviation company Lilium. 

Macron’s ambition to elevate Paris as a premier European business hub is underscored by these recent initiatives. While traditionally lagging behind global financial centers like New York and London, Paris aims to enhance its competitiveness. Despite its 14th position in the Z/Yen survey of global financial centers, published in March, the French capital is actively positioning itself for growth and investment in the pharmaceutical and financial sectors alike. 

Other News

The Dow’s Underperformance Signals Warnings and Insights

The Dow Jones’s recent slump compared to the S&P 500 suggests more than just market dynamics. Its lag mirrors the economy’s evolution and hints at significant market shifts, signaling investors to tread cautiously. 

ICBC Initiates TLAC Bond Sales with USD 4.15 Billion Issuance 

Industrial and Commercial Bank of China (ICBC) is set to issue 30 billion yuan (USD 4.15 billion) worth of Total Loss-Absorbing Capacity (TLAC) bonds on May 15, marking the first such issuance by a Chinese bank. 

Growing Concerns Over Leveraged Private Credit Market 

Elite financiers attending the Milken Institute conference in Los Angeles express apprehension over the surge in debt within the USD 1.7 trillion private credit market, drawing parallels to pre-2008 financial crisis risk-taking.

Share to

Industry Dynamics

Nvidia’s Surge Boosts Nasdaq Amid Rising Bond Yields 

Nvidia's shares soared again on Tuesday, continuing their significant recent gains on an otherwise subdued day for the stock market. 

2024-5-29 | Industry Dynamics

Saudi Wealth Fund to Restructure Management Amid Budget Strain 

Saudi Arabia's USD 925 billion sovereign wealth fund, the Public Investment Fund (PIF), is planning a major management reorganization to address rising costs and enhance investment success. 

2024-5-28 | Industry Dynamics

Oil Prices Steady as Markets Await OPEC+ Meeting

Oil prices remained largely unchanged in early Asian trading on Monday as the market anticipated the upcoming OPEC+ meeting on June 2. Producers are expected to discuss maintaining voluntary output cuts for the rest of the year. 

2024-5-27 | Industry Dynamics